{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:48:17Z","timestamp":1793998097644,"version":"4.8.0"},"reference-count":146,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016041","name":"Queen Elizabeth Hospital Birmingham Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009187","name":"Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000282","name":"Sir Jules Thorn Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000282","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000297","name":"Royal College of Surgeons of England","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000297","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jhep.2025.01.002","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T18:56:49Z","timestamp":1736362609000},"page":"1110-1124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cellular interactions in self-directed immune-mediated liver diseases"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6637-8952","authenticated-orcid":false,"given":"Amber G.","family":"Bozward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott P.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6025-6399","authenticated-orcid":false,"given":"Sean M.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8122-3139","authenticated-orcid":false,"given":"Kayani","family":"Kayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye H.","family":"Oo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2025.01.002_bib1","first-page":"10","article-title":"Breakdown in hepatic tolerance and its relation to autoimmune liver diseases","volume":"69","author":"Bozward","year":"2021","journal-title":"Minerva Gastroenterol (Torino)"},{"key":"10.1016\/j.jhep.2025.01.002_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaut.2009.07.011","article-title":"The role of chemokines in the recruitment of lymphocytes to the liver","volume":"34","author":"Oo","year":"2010","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jhep.2025.01.002_bib3","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.jhep.2012.07.008","article-title":"CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver","volume":"57","author":"Oo","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.01.002_bib4","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0002-9440(10)62060-3","article-title":"CXCR 3 activation promotes lymphocyte transendothelial migration across human hepatic endothelium under fluid flow","volume":"167","author":"Curbishley","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2025.01.002_bib5","first-page":"200","article-title":"Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis","volume":"12\/12","author":"Eksteen","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhep.2025.01.002_bib6","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/eji.1830270619","article-title":"Association between receptor density, cellular activation, and transformation of adhesive behavior of flowing lymphocytes binding to VCAM-1","volume":"27","author":"Lalor","year":"1997","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib7","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41575-018-0020-y","article-title":"Liver sinusoidal endothelial cells - gatekeepers of hepatic immunity","volume":"15","author":"Shetty","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.01.002_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2016-312354","article-title":"Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner","volume":"67","author":"Trivedi","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.01.002_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2023.12.023","article-title":"Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver","volume":"80","author":"Andrews","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.01.002_bib10","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jhep.2014.04.027","article-title":"TGF-beta-dependent induction of CD4(+)CD25(+)Foxp3(+) Tregs by liver sinusoidal endothelial cells","volume":"61","author":"Carambia","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.01.002_bib11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.21965","article-title":"Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8+ T cell tolerance","volume":"47","author":"Diehl","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.01.002_bib12","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000269","article-title":"CD4+ T-cell subsets in autoimmune hepatitis: a review","volume":"7","author":"Chen","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.01.002_bib13","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(20)31607-X","article-title":"Primary biliary cholangitis","volume":"396","author":"Lleo","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.jhep.2025.01.002_bib14","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1002\/hep.26979","article-title":"IL-12\/Th1 and IL-23\/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy","volume":"59","author":"Yang","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.01.002_bib15","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/hep.26447","article-title":"Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis","volume":"58","author":"Katt","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.01.002_bib16","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/ecco-jcc\/jjx050","article-title":"Th1 and innate lymphoid cells accumulate in primary sclerosing cholangitis-associated inflammatory bowel disease","volume":"11","author":"Gwela","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jhep.2025.01.002_bib17","article-title":"Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression","volume":"6","author":"Zhao","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2025.01.002_bib18","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/2211-5463.13148","article-title":"Tim-3 suppresses autoimmune hepatitis via the p38\/MKP-1 pathway in Th17 cells","volume":"11","author":"Wu","year":"2021","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.jhep.2025.01.002_bib19","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jhep.2022.06.014","article-title":"NUDT1 promotes the accumulation and longevity of CD103(+) T(RM) cells in primary biliary cholangitis","volume":"77","author":"Huang","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.01.002_bib20","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/hep.31739","article-title":"The clinical significance of hepatic CD69(+) CD103(+) CD8(+) resident-memory T cells in autoimmune hepatitis","volume":"74","author":"You","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.01.002_bib21","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1096\/fj.01-0088com","article-title":"CD40 activation-induced, Fas-dependent apoptosis and NF-kappaB\/AP-1 signaling in human intrahepatic biliary epithelial cells","volume":"15","author":"Afford","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.jhep.2025.01.002_bib22","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.cellsig.2005.05.015","article-title":"CD40 mediated human cholangiocyte apoptosis requires JAK2 dependent activation of STAT3 in addition to activation of JNK1\/2 and ERK1\/2","volume":"18","author":"Ahmed-Choudhury","year":"2006","journal-title":"Cell Signal"},{"key":"10.1016\/j.jhep.2025.01.002_bib23","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1084\/jem.189.2.441","article-title":"CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface fas ligand expression and amplifies fas-mediated hepatocyte death during allograft rejection","volume":"189","author":"Afford","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhep.2025.01.002_bib24","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hep.28517","article-title":"Human intrahepatic regulatory T cells are functional, require IL-2 from effector cells for survival, and are susceptible to Fas ligand-mediated apoptosis","volume":"64","author":"Chen","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.01.002_bib25","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/hep.26702","article-title":"CD8 T cells primed in the gut-associated lymphoid tissue induce immune-mediated cholangitis in mice","volume":"59","author":"Seidel","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.01.002_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.711217","article-title":"Gut-liver immune traffic: deciphering immune-pathogenesis to underpin translational therapy","volume":"12","author":"Bozward","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2010.10.005","article-title":"Liver antigen-presenting cells","volume":"54","author":"Crispe","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.01.002_bib28","first-page":"13","article-title":"Frontiers | Hepatocytes: a key role in liver inflammation","volume":"18","author":"Gong","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib29","article-title":"Tissue-resident and innate-like T cells in patients with advanced chronic liver disease","volume":"5","author":"Ibidapo-Obe","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.01.002_bib30","article-title":"Autoimmmune hepatitis","volume":"19","author":"Terziroli Beretta-Piccoli","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib31","first-page":"203","article-title":"TNF-producing Th1 cells are selectively expanded in liver infiltrates of patients with autoimmune hepatitis","volume":"12\/15","author":"Bovensiepen","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1192840","article-title":"Cholangiokines: undervalued modulators in the hepatic microenvironment","volume":"14","author":"Cai","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib33","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/path.5228","article-title":"High-throughput sequencing identifies aetiology-dependent differences in ductular reaction in human chronic liver disease","volume":"248","author":"Govaere","year":"2019","journal-title":"J Pathol"},{"key":"10.1016\/j.jhep.2025.01.002_bib34","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.4049\/jimmunol.174.2.1055","article-title":"CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver","volume":"174","author":"Heydtmann","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib35","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.1365-2249.2001.01391.x","article-title":"Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes","volume":"123","author":"Nishioji","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib36","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/HEP.0000000000000270","article-title":"Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression","volume":"78","author":"Guillot","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.01.002_bib37","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.1800455","article-title":"Bidirectional cross-talk between biliary epithelium and Th17 cells promotes local Th17 expansion and bile duct proliferation in biliary liver diseases","volume":"203","author":"Jeffery","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib38","doi-asserted-by":"crossref","DOI":"10.1189\/jlb.5A1015-469R","article-title":"CD4+ T cells from patients with primary sclerosing cholangitis exhibit reduced apoptosis and down-regulation of proapoptotic Bim in peripheral blood","volume":"101","author":"Schoknecht","year":"2017","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jhep.2025.01.002_bib39","doi-asserted-by":"crossref","first-page":"593","DOI":"10.4049\/jimmunol.177.1.593","article-title":"Epithelial inflammation is associated with CCL28 production and the recruitment of regulatory T cells expressing CCR101","volume":"177","author":"Eksteen","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib40","article-title":"Beyond FOXP3: a 20-year journey unravelling human regulatory T-cell heterogeneity","volume":"14","author":"Santosh Nirmala","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/hep4.2001","article-title":"Spatial transcriptomics identifies enriched gene expression and cell types in human liver fibrosis","volume":"6","author":"Chung","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.01.002_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31211","article-title":"Targeted apoptosis of ductular reactive cells reduces hepatic fibrosis in a mouse model of cholestasis","volume":"72","author":"Azad","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.01.002_bib43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41467-022-34606-w","article-title":"Unique DUOX2(+)ACE2(+) small cholangiocytes are pathogenic targets for primary biliary cholangitis","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2025.01.002_bib44","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jcmgh.2023.09.008","article-title":"The origin and fate of liver myofibroblasts","volume":"17","author":"Kim","year":"2024","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.01.002_bib45","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1053\/j.gastro.2008.10.020","article-title":"Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver","volume":"136","author":"Holt","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.01.002_bib46","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cld.2008.07.002","article-title":"Immune interactions in hepatic fibrosis","volume":"12","author":"Holt","year":"2008","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2025.01.002_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122547","article-title":"The evidence-based multifaceted roles of hepatic stellate cells in liver diseases: a concise review","volume":"344","author":"Kim","year":"2024","journal-title":"Life Sci"},{"key":"10.1016\/j.jhep.2025.01.002_bib48","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fimmu.2015.00068","article-title":"Interactions between CD44 and hyaluronan in leukocyte trafficking","volume":"6","author":"McDonald","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib49","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/hep.20885","article-title":"Early intrahepatic antigen-specific retention of na\u00efve CD8+ T cells is predominantly ICAM-1\/LFA-1 dependent in mice","volume":"42","author":"Bertolino","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.01.002_bib50","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.prp.2010.08.002","article-title":"Relationship between plasma cells and hepatic stellate cells in autoimmune hepatitis","volume":"206","author":"Brandao","year":"2010","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.jhep.2025.01.002_bib51","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.annonc.2022.07.1940","article-title":"Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response","volume":"33","author":"Loibl","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2025.01.002_bib52","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.19.01213","article-title":"Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer","volume":"38","author":"Vuky","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2025.01.002_bib53","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.01.002_bib54","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.7150\/jca.49325","article-title":"Comparative efficacy and safety of PD-1\/PD-L1 inhibitors for patients with solid tumors: a systematic review and bayesian network meta-analysis","volume":"12","author":"Huang","year":"2021","journal-title":"J Cancer"},{"key":"10.1016\/j.jhep.2025.01.002_bib55","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/hep.31227","article-title":"Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation","volume":"72","author":"Peeraphatdit","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.01.002_bib56","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1053\/j.semdp.2019.07.009","article-title":"Checkpoint inhibitor-induced liver injury: a novel form of liver disease emerging in the era of cancer immunotherapy","volume":"36","author":"Zen","year":"2019","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.jhep.2025.01.002_bib57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jhep.2025.01.002_bib58","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2025.01.002_bib59","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1093\/annonc\/mdx403","article-title":"Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies","volume":"28","author":"Collins","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2025.01.002_bib60","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jhep.2023.04.033","article-title":"Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): an expert opinion meeting report","volume":"79","author":"Andrade","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.01.002_bib61","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/cei.12558","article-title":"Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis","volume":"180","author":"Foureau","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005635","article-title":"Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events","volume":"10","author":"Coukos","year":"2022","journal-title":"J ImmunoTherapy Cancer"},{"key":"10.1016\/j.jhep.2025.01.002_bib63","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury","volume":"31","author":"Zen","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jhep.2025.01.002_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00650","article-title":"Cell-in-Cell structures in the liver: a tale of four E\u2019s","volume":"11","author":"Davies","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib65","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/nrm2504","article-title":"The cell biology of cell-in-cell structures","volume":"9","author":"Overholtzer","year":"2008","journal-title":"Nat Rev Mol Cel Biol"},{"key":"10.1016\/j.jhep.2025.01.002_bib66","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.cell.2007.10.040","article-title":"A nonapoptotic cell death process, entosis, that occurs by cell-in-cell invasion","volume":"131","author":"Overholtzer","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2025.01.002_bib67","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3389\/fimmu.2018.00044","article-title":"Clearance of apoptotic cells by tissue epithelia: a putative role for hepatocytes in liver efferocytosis","volume":"9","author":"Davies","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib68","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2141.1956.tb06700.x","article-title":"Biological interaction between lymphocytes and. Other cells","volume":"2","author":"Humble","year":"1956","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jhep.2025.01.002_bib69","doi-asserted-by":"crossref","first-page":"16735","DOI":"10.1073\/pnas.1112251108","article-title":"Hepatocyte entry leads to degradation of autoreactive CD8 T cells","volume":"108","author":"Benseler","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2025.01.002_bib70","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/ncb2363","article-title":"Autophagy machinery mediates macroendocytic processing and entotic cell death by targeting single membranes","volume":"13","author":"Florey","year":"2011","journal-title":"Nat Cel Biol"},{"key":"10.1016\/j.jhep.2025.01.002_bib71","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.celrep.2019.09.068","article-title":"Hepatocytes delete regulatory T cells by enclysis, a CD4(+) T cell engulfment process","volume":"29","author":"Davies","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhep.2025.01.002_bib72","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/jcmm.14752","article-title":"Emperipolesis mediated by CD8 + T cells correlates with biliary epithelia cell injury in primary biliary cholangitis","volume":"24","author":"Zhao","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jhep.2025.01.002_bib73","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/s41467-024-44910-2","article-title":"Expression of E-cadherin by CD8(+) T cells promotes their invasion into biliary epithelial cells","volume":"15","author":"Davies","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2025.01.002_bib74","first-page":"1","article-title":"Viral and autoimmune hepatitis. Morphologic and pathogenetic aspects of cell damage in hepatitis with potential chronicity","volume":"132","author":"Dienes","year":"1989","journal-title":"Veroffentlichungen aus der Pathologie"},{"key":"10.1016\/j.jhep.2025.01.002_bib75","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s12016-014-8432-0","article-title":"Emperipolesis mediated by CD8 T cells is a characteristic histopathologic feature of autoimmune hepatitis","volume":"48","author":"Miao","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib76","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/s12276-024-01227-w","article-title":"Entosis: the core mechanism and crosstalk with other cell death programs","volume":"56","author":"Kim","year":"2024","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.jhep.2025.01.002_bib77","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib78","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jhep.2025.01.002_bib79","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib80","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1084\/jem.188.2.287","article-title":"CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production","volume":"188","author":"Thornton","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhep.2025.01.002_bib81","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fimmu.2012.00178","article-title":"Multiple treg suppressive modules and their adaptability","volume":"3","author":"Wing","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib82","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/83713","article-title":"The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3","volume":"27","author":"Bennett","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2025.01.002_bib83","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/83707","article-title":"X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy","volume":"27","author":"Wildin","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2025.01.002_bib84","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/83784","article-title":"Disruption of a new forkhead\/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse","volume":"27","author":"Brunkow","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2025.01.002_bib85","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jaut.2014.01.034","article-title":"Murine autoimmune cholangitis requires two hits: cytotoxic KLRG1(+) CD8 effector cells and defective T regulatory cells","volume":"50","author":"Huang","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jhep.2025.01.002_bib86","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/cei.12940","article-title":"Low-dose interleukin-2 promotes STAT-5 phosphorylation, T(reg) survival and CTLA-4-dependent function in autoimmune liver diseases","volume":"188","author":"Jeffery","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib87","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.jhep.2025.01.002_bib88","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw0902","article-title":"CTLA-4\u2013mediated transendocytosis of costimulatory molecules primarily targets migratory dendritic cells","volume":"4","author":"Ovcinnikovs","year":"2019","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib89","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jhep.2012.02.029","article-title":"FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency","volume":"57","author":"Peiseler","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.01.002_bib90","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jhep.2014.05.034","article-title":"Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies","volume":"61","author":"Taubert","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.01.002_bib91","doi-asserted-by":"crossref","first-page":"7083","DOI":"10.1073\/pnas.1620835114","article-title":"IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors","volume":"114","author":"Whitehouse","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2025.01.002_bib92","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.intimp.2018.09.027","article-title":"miR-181a regulates Th17 cells distribution via up-regulated BCL-2 in primary biliary cholangitis","volume":"64","author":"Song","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jhep.2025.01.002_bib93","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.21123","article-title":"Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis","volume":"43","author":"Lan","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.01.002_bib94","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/cmi.2010.40","article-title":"CD4+ CD25+ but not CD4+ Foxp3+ T cells as a regulatory subset in primary biliary cirrhosis","volume":"7","author":"Wang","year":"2010","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib95","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/cei\/uxad117","article-title":"Regulatory T cells in inflamed liver are dysfunctional in murine primary biliary cholangitis","volume":"215","author":"Lin","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib96","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jaut.2010.06.004","article-title":"Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis","volume":"35","author":"Bernuzzi","year":"2010","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jhep.2025.01.002_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102619","article-title":"Regulatory T cells in autoimmune hepatitis: an updated overview","volume":"119","author":"Longhi","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jhep.2025.01.002_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104195","article-title":"The hepatic microenvironment and regulatory T cells","volume":"357","author":"Osei-Bordom","year":"2020","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib99","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/hep.27884","article-title":"In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression","volume":"62","author":"Liberal","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.01.002_bib100","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jhep.2013.12.027","article-title":"Reduced FOXP3(+) regulatory T cells in patients with primary sclerosing cholangitis are associated with IL2RA gene polymorphisms","volume":"60","author":"Sebode","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.01.002_bib101","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.04.003","article-title":"Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis","volume":"147","author":"Liaskou","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.01.002_bib102","doi-asserted-by":"crossref","DOI":"10.1111\/jgh.15463","article-title":"Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn's disease","volume":"36","author":"Matsuoka","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.01.002_bib103","first-page":"9","article-title":"Frontiers | the critical role of chemokine (C\u2013C Motif) receptor 2-positive monocytes in autoimmune cholangitis","author":"Reuveni","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib104","doi-asserted-by":"crossref","DOI":"10.1002\/hep4.1619","article-title":"Efficacy and safety of cenicriviroc in patients with primary sclerosing cholangitis: PERSEUS study","volume":"5","author":"Eksteen","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.01.002_bib105","doi-asserted-by":"crossref","DOI":"10.1002\/hep4.1170","article-title":"NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid","volume":"2","author":"Graaf","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.01.002_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/antib12020030","article-title":"CCR6 as a potential target for therapeutic antibodies for the treatment of inflammatory diseases","volume":"12","author":"G\u00f3mez-Melero","year":"2023","journal-title":"Antibodies"},{"key":"10.1016\/j.jhep.2025.01.002_bib107","doi-asserted-by":"crossref","DOI":"10.1111\/apt.13398","article-title":"Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease","volume":"42","author":"Feagan","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.01.002_bib108","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000426","article-title":"Vascular adhesion protein-1 blockade in primary sclerosing cholangitis: open-label, multicenter, single-arm, phase II trial","volume":"8","author":"Hirschfield","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.01.002_bib109","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cgh.2019.05.013","article-title":"Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases","volume":"18","author":"Lynch","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.01.002_bib110","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41423-022-00904-y","article-title":"Treatment with a JAK1\/2 inhibitor ameliorates murine autoimmune cholangitis induced by IFN overexpression","volume":"19","author":"Shao","year":"2022","journal-title":"Cel Mol Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2021.100107","article-title":"Baricitinib and primary biliary cholangitis","volume":"4","author":"Gordon","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.jhep.2025.01.002_bib112","article-title":"Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis","volume":"3","author":"Weiler-Normann","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.01.002_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.02.014","article-title":"Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis","author":"Hedin","year":"2020","journal-title":"Clinical Gastroenterology Hepatology"},{"key":"10.1016\/j.jhep.2025.01.002_bib114","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12876-024-03176-0","article-title":"The effects of low-dose IL-2 on Th17\/Treg cell imbalance in primary biliary cholangitis mouse models","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2025.01.002_bib115","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/hep.30059","article-title":"Low-dose interleukin-2 for refractory autoimmune hepatitis","volume":"68","author":"Lim","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.01.002_bib116","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jhepr.2019.10.005","article-title":"Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: results from the international autoimmune hepatitis group","volume":"1","author":"Than","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.01.002_bib117","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/gutjnl-2022-327075","article-title":"Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis","volume":"72","author":"Voskens","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.01.002_bib118","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jhepr.2019.08.001","article-title":"Liver homing of clinical grade Tregs after therapeutic infusion in patients with autoimmune hepatitis","volume":"1","author":"Oo","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.01.002_bib119","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.clim.2009.06.001","article-title":"First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells","volume":"133","author":"Trzonkowski","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib120","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.omtm.2018.01.006","article-title":"A rapamycin-based GMP-compatible process for the isolation and expansion of regulatory T cells for clinical trials","volume":"8","author":"Fraser","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jhep.2025.01.002_bib121","article-title":"Strong expansion of human regulatory T cells for adoptive cell therapy results in epigenetic changes which may impact their survival and function","volume":"9","author":"Ou","year":"2021","journal-title":"Front Cel Dev Biol"},{"key":"10.1016\/j.jhep.2025.01.002_bib122","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00281-022-00940-w","article-title":"Challenges and opportunities in achieving effective regulatory T cell therapy in autoimmune liver disease","volume":"44","author":"Richardson","year":"2022","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jhep.2025.01.002_bib123","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1002\/eji.200939432","article-title":"Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD","volume":"39","author":"Koenecke","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib124","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.it.2016.08.012","article-title":"Induced regulatory T cells: their development, stability, and applications","volume":"37","author":"Kanamori","year":"2016","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib125","article-title":"Barriers to Treg therapy in Europe: from production to regulation","volume":"10","author":"Hennessy","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jhep.2025.01.002_bib126","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"T(reg) cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib127","doi-asserted-by":"crossref","first-page":"12258","DOI":"10.1073\/pnas.1922600117","article-title":"Epigenetic conversion of conventional T cells into regulatory T cells by CD28 signal deprivation","volume":"117","author":"Mikami","year":"2020","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jhep.2025.01.002_bib128","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw2707","article-title":"Conversion of antigen-specific effector\/memory T cells into Foxp3-expressing Treg cells by inhibition of CDK8\/19","volume":"4","author":"Akamatsu","year":"2019","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib129","article-title":"P41 Conversion of CD4+ T cells to functioning and epigenetically stable induced regulatory T cells in patients with primary biliary cholangitis","volume":"72","author":"Kayani","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.01.002_bib130","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1053\/j.gastro.2021.02.061","article-title":"X chromosome contribution to the genetic architecture of primary biliary cholangitis","volume":"160","author":"Asselta","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.01.002_bib131","article-title":"Building a CAR-Treg: going from the basic to the luxury model","volume":"358","author":"Rosado-S\u00e1nchez","year":"2020","journal-title":"Cel Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib132","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.ekir.2022.03.030","article-title":"Study design: human leukocyte antigen class I molecule A(\u2217)02-Chimeric antigen receptor regulatory T cells in renal transplantation","volume":"7","author":"Schreeb","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jhep.2025.01.002_bib133","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41434-022-00358-x","article-title":"Preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplantation","volume":"30","author":"Proics","year":"2023","journal-title":"Gene Ther"},{"key":"10.1016\/j.jhep.2025.01.002_bib134","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.4049\/jimmunol.177.8.5115","article-title":"Selective availability of IL-2 is a major determinant controlling the production of CD4+CD25+Foxp3+ T regulatory cells","volume":"177","author":"Yu","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2025.01.002_bib135","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","article-title":"Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.jhep.2025.01.002_bib136","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173107","article-title":"A humanized IL-2 mutein expands Tregs and prolongs transplant survival in preclinical models","volume":"134","author":"Efe","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2025.01.002_bib137","volume":"11","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2025.01.002_bib138","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2019.04.006","article-title":"A review of bispecific antibodies and antibody constructs in oncology and clinical challenges","volume":"201","author":"Suurs","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jhep.2025.01.002_bib139","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2025.01.002_bib140","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","article-title":"CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.01.002_bib141","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2025.01.002_bib142","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.01.002_bib143","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41557-023-01280-4","article-title":"Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer","volume":"15","author":"Szijj","year":"2023","journal-title":"Nat Chem"},{"key":"10.1016\/j.jhep.2025.01.002_bib144","doi-asserted-by":"crossref","first-page":"28059","DOI":"10.18632\/oncotarget.8574","article-title":"Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcgamma receptors","volume":"7","author":"Borlak","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2025.01.002_bib145","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.3390\/curroncol30070467","article-title":"Toxicity profile of chimeric antigen receptor T-cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management","volume":"30","author":"Markouli","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jhep.2025.01.002_bib146","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.152468","article-title":"Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors","volume":"6","author":"Curnock","year":"2021","journal-title":"JCI Insight"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825000066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825000066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:01:41Z","timestamp":1773457301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827825000066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":146,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0168827825000066"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2025.01.002","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular interactions in self-directed immune-mediated liver diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2025.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}